Larvol Delta - Viracta-receives-welcome-FDA-guidance-at-type-C-meeting-for-the-treatment-of-EBVassociated-lymphomas

nanatinostat (VRx-3996) - Viracta Therapeutics

https://www.prnewswire.com/news-releases/viracta-receives-welcome-fda-guidance-at-type-c-meeting-for-the-treatment-of-ebv-associated-lymphomas-301037241.html

Apr 8, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next